Given the conspicuous role of brain inflammation and activated astrocytes in AD pathobiology, we undertook genetic and pharmacological approaches to target S100B in order to explore a putative causal relationship between S100B and progression of AD-like pathology. This evidence concerns the gene S100B and Alzheimer disease.